NeonMind Obtains Health Canada Approval to Advance Psilocybin Research

Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) ("Better Plant") or (the "Company") is pleased to announce that its majority owned subsidiary NeonMind Biosciences Inc. ("NeonMind") has obtained Health Canada approval to advance its preclinical trial on psilocybin-based research (the "Trial").

Figure 1: NeonMind Obtains Health Canada Approval to Advance Psilocybin Research

To view an enhanced version of Figure 1, please visit:
https://orders.newsfilecorp.com/files/6377/68036_e90bf796e44c9873_001full.jpg

The Trial is intended to determine the capacity of psilocybin to dose-dependently cause weight loss and prevent weight gain, measuring glucose metabolism, weight loss and effect on food cravings.

NeonMind has engaged the University of British Columbia (the "University") to conduct the Trial. The services are provided by the University under the supervision of Dr. Alasdair Barr, Department of Anesthesiology, Pharmacology & Therapeutics, Faculty of Medicine, who is authorized by Health Canada to act as the Principal Investigator for the Trial (the "Principal Investigator").

Dr. Barr is a tenured faculty member at the University and has extensive experience working with controlled substances as part of his research. His doctoral and post-doctoral research involved a significant body of work using controlled substances.

Before psilocybin, a restricted substance, can be used for a scientific purpose in Canada, the Canadian Minister of Health must grant authority or an exemption pursuant to Subsection 56 of the Controlled Drugs and Substances Act, S.C. 1996, c. 19.

On July 27, 2020, an application regarding the NeonMind Trial was submitted to Health Canada and on October 7, 2020, pursuant to section J.01.059 of Part J of the Food and Drug Regulations (FDR), Health Canada granted authorization to the Principal Investigator to carry out the Trial using psilocybin at UBC.

About NeonMind Biosciences Inc.

The NeonMind team marries ancient Ayurvedic wisdom with modern science, delivering high quality formulations that put health and wellness at the forefront for each of its unique coffee blends. In addition to its medicinal mushroom products, NeonMind is developing patent pending intellectual property for therapeutic uses of psilocybin, the psychedelic substance in magic mushrooms. Health Canada has approved NeonMind's preclinical trial for research of psilocybin as a treatment for weight loss and NeonMind is currently developing protocols for Phase II human trials to be submitted for approval in early 2021.

NeonMind's product candidates with psychedelic compounds will not be commercialized prior to applicable regulatory approval, which will only be granted if clinical evidence of safety and efficacy for the intended uses is successfully developed. Psilocybin is currently a Schedule III drug under the Controlled Drugs and Substances Act (CDSA) and it is a criminal offence to possess substances under the CDSA without a prescription. Health Canada has not approved psilocybin as a drug.

About Better Plant Sciences Inc.

Through its integrated business model, Better Plant develops, manufactures, markets, sells and distributes plant-based products. It has an extensive catalogue of over 400 proprietary product formulas. It operates websites and sells through eCommerce, Amazon and through a retail store network over 150 plant-based products for body, baby, and home under the brands JUSU, Urban Juve, and Wright & Well. Better Plant owns approximately 52% of NeonMind's issued and outstanding shares.

For more information about Better Plant, visit www.betterplantsciences.comor follow @betterplantsciences on Instagram.

Investor Relations Contact:

Penny White, President & CEO

Ali Dumanski, Investor Relations

invest@betterplantsciences.com

1-833-514-2677

The Canadian Securities Exchange has not reviewed, approved or disapproved the contents of this news release.

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking information and statements (collectively, "forward looking statements") under applicable Canadian securities legislation. Forward-looking statements are necessarily based upon a number of estimates, forecasts, beliefs and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such risks, uncertainties and factors include, but are not limited to: risks related to the development, testing, licensing, brand development, availability of packaging, intellectual property protection, reduced global commerce and reduced access to raw materials and other supplies due to the spread of COVID-19, the potential for not acquiring any rights as a result of the patent application and any products making use of the intellectual property may be ineffective or the company may be unsuccessful in commercializing them; and other approvals will be required before commercial exploitation of the intellectual property can happen. Demand for the company's products, general business, economic, competitive, political and social uncertainties, delay or failure to receive board or regulatory approvals where applicable, and the state of the capital markets. Better Plant cautions readers not to place undue reliance on forward-looking statements provided by Better Plant, as such forward-looking statements are not a guarantee of future results or performance and actual results may differ materially. The forward-looking statements contained in this press release are made as of the date of this press release, and Better Plant expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

Corporate Logo

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/68036

News Provided by Newsfile via QuoteMedia

Better Plant Sciences CNX:PLNT VEGGF Cannabis Investing

Trulieve Partners with Black Buddha Cannabis to Launch Premium Products in Arizona and Pennsylvania

Trulieve Cannabis Corp. (CSE: TRUL ) (OTCQX: TCNNF ) ("Trulieve" or "the Company"), a leading and top-performing medical marijuana company in the U.S., today announces a partnership with Black Buddha Cannabis a purpose-driven and women-owned medical marijuana brand. The collaboration will introduce Black Buddha Cannabis products to Trulieve dispensaries in Arizona and Pennsylvania starting in October 2024 .

Black Buddha Cannabis, founded by Roz McCarthy , CEO of Soaring High Industries and Minorities for Medical Marijuana, brings a unique approach to the medical marijuana industry with a focus on wellness and healing. McCarthy, a 30+ year healthcare industry veteran and a 2018 honoree in High Times' 100 Most Influential People, launched Black Buddha Cannabis after a traumatic brain injury that transformed her life and inspired her to explore the therapeutic benefits of medical marijuana.

Products from Black Buddha's "BLYSS" and "DREAM" lines of premium medical marijuana flower will be available in Trulieve stores throughout Arizona and Pennsylvania starting Friday, October 4 . Black Buddha products are curated for a blissful experience by focusing on terpene profiles and enhanced therapeutic effects that cater to a balanced lifestyle.

"We are incredibly excited to bring Black Buddha Cannabis to the vibrant markets of Arizona and Pennsylvania ," says Black Buddha Cannabis Chief Executive Officer Roz McCarthy . "Our brand is deeply rooted in wellness, and our mission is to help people feel better, whether they are part of the adult-use or medical marijuana community. We believe everyone deserves access to products that enhance their well-being, and we're thrilled to offer our carefully curated flower lines to these new markets."

Trulieve's partnership with Black Buddha Cannabis marks a significant milestone in expanding the Company's product offerings and supporting brands that align with Trulieve's commitment to wellness, innovation, and quality. This collaboration is expected to resonate with customers who seek premium medical marijuana crafted with intention and care.

"We are excited to welcome Black Buddha Cannabis to our product lineup," said Trulieve's Chief Executive Officer Kim Rivers . "Roz's inspiring story and her brand's dedication to healing through medical marijuana align perfectly with Trulieve's mission to provide high-quality, purpose-driven products to our customers."

Arizona and Pennsylvania will serve as the target markets for the initial launch of the partnership, a collaboration that underscores Trulieve's ongoing commitment to offering high-quality and innovative products that cater to the diverse needs of its customers.

For more information on Black Buddha Cannabis, please visit BlackBuddha.co . Visit Trulieve.com to find store locations, sign up for updates and shop for products online.

About Black Buddha Cannabis
Black Buddha Cannabis establishes a new paradigm for the industry as a black-owned, environmentally conscious, wellness-focused, and social equity-driven brand. Black Buddha Cannabis' premiere lifestyle and wellness products will be found at leading dispensaries across the country through state-by-state brand partnerships with manufacturers, cultivators, and operators. Currently available in Ohio , Nevada and Massachusetts , Black Buddha Cannabis expects to have products available in New Jersey in January 2025 . To learn more about Black Buddha Cannabis please visit http://blackbuddha.co .

About Trulieve
Trulieve is an industry-leading, vertically integrated medical marijuana company and multi-state operator in the U.S., with leading market positions in Arizona , Florida , and Pennsylvania . Trulieve is poised for accelerated growth and expansion, building scale in retail and distribution in new and existing markets through its hub strategy. By providing innovative, high-quality products across its brand portfolio, Trulieve delivers optimal customer experiences and increases access to medical marijuana, helping patients and customers to live without limits. Trulieve is listed on the CSE under the symbol TRUL and trades on the OTCQX market under the symbol TCNNF. For more information, please visit Trulieve.com .

Facebook: @Trulieve
Instagram: @Trulieve _
X: @Trulieve

Investor Contact
Christine Hersey , Vice President of Investor Relations
+1 (424) 202-0210
Christine.Hersey@Trulieve.com

Media Contact
Phil Buck , APR, Corporate Communications Manager
+1 (406) 370-6226
Philip.Buck@Trulieve.com

View original content to download multimedia: https://www.prnewswire.com/news-releases/trulieve-partners-with-black-buddha-cannabis-to-launch-premium-products-in-arizona-and-pennsylvania-302263424.html

SOURCE Trulieve Cannabis Corp.

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/October2024/01/c1475.html

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Trulieve Announces Upcoming Event Participation

Trulieve Cannabis Corp. (CSE: TRUL ) (OTCQX: TCNNF ) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., today announced planned event participation.

ATB Capital Markets 2024 Life Sciences Institutional Investor Conference, September 18, 2024 : Vice President of Investor Relations Christine Hersey will participate in investor meetings.
Benzinga Cannabis Capital Conference, October 8 - 9, 2024 : Chief Marketing Officer Gina Collins will participate in a panel discussion on Next-Gen Cannabis Retail on October 9th at 11:00 AM , and Vice President of Investor Relations Christine Hersey will participate in a VIP Roundtable discussion on Capital Markets and investor meetings.

Information about our events, links to events where available, and slide presentations can be found at: https://investors.trulieve.com/events

About Trulieve

Trulieve is an industry leading, vertically integrated cannabis company and multi-state operator in the U.S., with leading market positions in Arizona , Florida , and Pennsylvania . Trulieve is poised for accelerated growth and expansion, building scale in retail and distribution in new and existing markets through its hub strategy. By providing innovative, high-quality products across its brand portfolio, Trulieve delivers optimal customer experiences and increases access to cannabis, helping patients and customers to live without limits. Trulieve is listed on the CSE under the symbol TRUL and trades on the OTCQX market under the symbol TCNNF. For more information, please visit Trulieve.com.

Facebook: @Trulieve
Instagram: @Trulieve _
X: @Trulieve

Investor Contact
Christine Hersey , Vice President of Investor Relations
+1 (424) 202-0210
Christine.Hersey@Trulieve.com

Media Contact
Phil Buck , APR, Corporate Communications Manager
+1 (406) 370-6226
Philip.Buck@Trulieve.com

View original content to download multimedia: https://www.prnewswire.com/news-releases/trulieve-announces-upcoming-event-participation-302245660.html